A Phase 2 Clinical Trial of multi-agent Chemotherapy or letrozole plus Ribociclib (LEE011) as neoadjuvant treatment for postmenopausal patients with Luminal B/HER2-negative breast cancer. Protocol: SOLTI-1402
A Two-Part, Open-Label, Randomized, Phase II/III Study of Dinutuximab and Irinotecan versus Irinotecan for Second Line Treatment of Subjects with Relapsed or Refractory Small Cell Lung Cancer. Protocol: DIV-301
A randomized, open label phase 3 study to evaluate the safety and efficacy of mirvetuximab soravtansine (IMGN853) versus investigator’s choice of chemotherapy in women with folate receptor α-positive advanced epithelial ovarian cancer, primary peritoneal cancer or fallopian tube cancer.
Phase 2 Study of Carboplatin, Etoposide, and Atezolizumab With or Without Trilaciclib (G1T28) in Patients with Untreated Extensive-Stage Small Cell Lung Cancer. Protocol: G1T28-05
Phase III multicenter, randomized study of atezolizumab versus placebo administered in combination with paclitaxel, carboplatin, and bevacizumab in patients with newly diagnosed ovarian, fallopian tube or primary peritoneal cancer, stage III or IV.
Phase III, open label, multicenter trial of avelumab (MSB0010718C) versus platinum doublet in first line for recurrent or stage IV PD-L1+ non-small-cell lung cancer. Protocol: EMR100070-005
Prospective, double blind, randomized phase III clinical trial, of adjuvant chemotherapy with MEDI4736 vs placebo in non-small-cell lung cancer patients following complete resection.
